A combo drug called valsartan-hydrochlorothiazide is used to treat high blood pressure. (hypertension). Valsartan, a member of the angiotensin receptor blocker (ARB) class of medications, and hydrochlorothiazide, a diuretic or “water pill,” are its two active components.
While hydrochlorothiazide aids in lowering the body’s salt and water content, which also decreases blood pressure, valsartan acts by relaxing blood vessels to lower blood pressure.
This drug should be taken at the same time every day, once daily, with or without meals. It’s crucial to adhere to your doctor’s dosage recommendations and to never stop taking this medicine without first talking to your doctor.
Dizziness, headaches, weariness, and increased urination are typical adverse effects of valsartan-hydrochlorothiazide. Additionally, some people may get more severe adverse effects from it, such as kidney issues or allergic responses.
Before beginning therapy with valsartan-hydrochlorothiazide, it is crucial to discuss any potential dangers and benefits with your doctor. This is true of any medicine.
Global valsartan-hydrochlorothiazide market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
Exforge HCT (amlodipine, valsartan, hydrochlorothiazide), the only blood pressure (BP) treatment that combines three drugs in a single pill, has been approved by the US Food and Drug Administration (FDA).
Exforge HCT is a crucial new alternative for individuals who have tried using dual combinations of these blood pressure drugs without success. It combines the most commonly prescribed calcium channel blocker, angiotensin receptor blocker, and diuretic in one pill.
Patients with moderate to severe hypertension can experience proven success with Exforge HCT. In a clinical trial, the maximum dose of Exforge HCT (amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg) significantly reduced systolic and diastolic blood pressure when compared to all dual combinations of its components at the same doses (valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg.
Exforge HCT significantly lowers systolic and diastolic blood pressure compared to valsartan/hydrochlorothiazide, amlodipine/valsartan, and amlodipine/hydrochlorothiazide by 7.6/5.0 mmHg, 6.2/3.3 mmHg, and 8.2/5.3 mmHg, respectively.
There is also an unmeasured placebo impact in these outcomes. Ambulatory blood pressure monitoring revealed that Exforge HCT’s blood pressure-lowering impact persisted for the entire 24-hour period.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.